Research Output Journal of Biological and Applied Science 5(3):119-125, 2025

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

https://doi.org/10.59298/ROJBAS/2025/53119125

The Future of Vaccinology: Engineering New Vaccines

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

ABSTRACT

Vaccinology has undergone a transformative evolution from its early empirical roots to a modern, highly interdisciplinary science driven by molecular biology, bioinformatics, and systems immunology. This paper explores the historical milestones and current technological advancements in vaccine development, with a particular focus on reverse and structural vaccinology, virus-like particles (VLPs), and genome-based approaches. Despite tremendous progress, vaccine development remains complex, expensive, and time-consuming, particularly for pathogens like HIV, tuberculosis, and malaria, which require more advanced strategies to elicit strong cellular immune responses. The role of immunology is crucial in designing effective vaccines, as it informs both antigen selection and delivery mechanisms. Emerging trends, such as vaccinomics and personalized vaccination, offer promise for tailoring immune responses and increasing efficacy. However, ethical concerns, vaccine hesitancy, logistical barriers, and unequal global access continue to challenge implementation. Global initiatives, particularly in low-resource settings, emphasize the need for coordinated efforts among governments, industry, and international health organizations. Ultimately, the future of vaccinology will be defined by the integration of innovative technologies, equitable distribution strategies, and global health priorities.

Keywords: Vaccinology, Reverse vaccinology, Structural vaccinology, Virus-like particles (VLPs), Vaccine engineering, Immunology, Vaccine development, Personalized vaccines.

INTRODUCTION

Vaccinology is a key area in biotechnology focused on vaccine development, emphasizing the understanding of immune mechanisms to combat infectious diseases. Major developments occurred in the last century with living attenuated virus vectors and subunit vaccines leading to licensed vaccines. However, challenges remain for diseases like HIV, malaria, and tuberculosis due to the absence of effective vaccines. The field has evolved into two main branches: surveyive and reverse vaccinology, with structural vaccinology emerging in the 1990s. This approach uses bioinformatics to forecast potential epitopes from protein sequences, particularly focusing on T cell epitopes of significant proteins. Structure and reverse vaccinology contribute to vaccination bioinformatics, highlighting their role in vaccine discovery. Historically, vaccine development often borrowed from animal vaccines, with early research being limited in scope. Technological advancements since the 1980s have transformed vaccine discovery, particularly through the availability of pathogen genome sequences. This led to the rise of reverse vaccinology as a method for designing new vaccines. Current genomic efforts focus on various pathogens and include wide-ranging sequencing from hosts, enabling the exploration of genetic variations through methods like SNPs, microRNA, and transcriptomic sequencing [1, 2].

Historical Perspectives on Vaccines

The earliest vaccines were crude materials from natural sources. Edwin Jenner discovered cowpox inoculation for vaccination against smallpox in 1796, Karl Landsteiner discovered polio and hepatitis B viruses late in the 20th century, and S. Hayflick developed the artificial attenuation of poliovirus strains. However, for long-lived viral diseases like hepatitis B (notably chronic hepatitis), the classical procedures were not feasible. Robert Chanock completed the cut-off of the improved type 7 virus by recombination in

the 1970s, and Pope et al. obtained the process on a pilot scale. Since then, vaccines against viral infections have all been developed by vaccine engineers with commercial and industrial procedures. There were no safety issues with cell culture vaccines. The comparative safety of vaccines of the heat-inactivated strains with those of classical and cell cultures is discussed for the inactivated candidates. Antigen drift may result in changes in immunity to disease states, as in the case of the microbe-like particles. The hepatitis B gene vaccines were an improvement since immunogenicity and coverage are combined. The pursuit of a vaccine against HIV was a challenge due to the animal reservoir, rapid mutation, and multiple receptors. The VP I capsule induction of IgA lymphocytes and nAbs opposed to the granulocyte-targeting protein G could enhance safety and efficacy. There is more emphasis on experimental procedures than on potential targets in the development of vaccines against a wide variety of infectious agents, especially against the major new threats to good health. Vaccines with all neglected pathogens from Niche, including a variety of agents, acellular vaccines, virion-passed viruses, similar neglected strains, transiently infective particles, recombinants arising after co-cultivation of ecologically similar strains, plant and parasite-derived products, new approaches to inactivated and recombinant vaccines, and hybrid protections, remain to be studied. There are possible targets for vaccines for the prevention of multiple diseases through a single encounter based on the construction of calculations of exposure severity and duration, and recombinant DNA [3, 4].

Current Vaccine Technologies

Most current vaccines were designed targeting pathogens that exhibit low antigenic variability and depend on antibody-mediated immunity for protection. This is the case for polio, tetanus, diphtheria, measles, hepatitis B, and others. For vaccine candidates capable of generating neutralizing or opsonizing antibodies against these pathogens, extensively vaccinated populations exhibited substantial epidemiological impact, thus an important reason to encourage further investment in vaccine research. For some diseases, such as rotavirus, changes in the virus genotype and serotype are observed in regions after vaccine introduction. Similarly, for subtypes H3N2, H5N1, and recently, H1N1 of the Influenza A virus, minor antigenic variability was responsible for the annual introduction of a new vaccine. In general, for these diseases, successful vaccinations occurred against pathogens able to propagate in extracellular compartments. On the other hand, important cell-mediated immunity against intracellular pathogens, especially those with poorly understood immunobiology, is difficult to obtain using current vaccine strategies. Moreover, live attenuated pathogen vaccines offer great potential risks, as two live attenuated vaccines for polio, one consisting of attenuated virus strains and the other of a recombinant virus strain expressing an attenuated capsid protein at the site of a chronic infection, provided a dormant and thus virulent origin for the emergence of pathogenic variants. The first ones were responsible for several cases of vaccine-derived polio in West Africa, and the second ones for the emergence of Chikungunya virus with a change in the spectrum of diseases [5, 6].

The Role of Immunology in Vaccine Development

Immunology, Spatial Technologies, Podocalyxin, Vaccines

The role of immunology in vaccine development has evolved. Initially based on descriptive studies of antibody-mediated disease, this field progressed through controlled population studies of vaccines themselves, followed by correlative studies that revealed immunological correlates of vaccine efficacy. More recently, these correlates have been exploited in the design of new vaccines and in identifying compositions for those that are already licensed. The explosion of molecular technologies, especially high-throughput methods to probe the expression, abundance, and modification of newly discovered immune cell types and their products, should be expected to radically alter vaccinal immunology. Not only will these new technologies help produce new vaccines by devising new combinations, but they will also increase understanding of potentially novel interventions to control the duration/effectiveness of existing vaccines. They will also provide new tools to examine questions that have been historically difficult to address. The second session of this review contains five contributions that consider various aspects of this evolving field. The first article discusses the nature and potential roles of newly discovered class II molecules that present peptide to previously unappreciated CD4-T-cell populations. Since these cells are products of a pathway that is also involved in virus and regulatory T cells, the burden of proof to show that these cells can contribute positively to vaccine efficacy is high. However, there is tantalizing evidence that they can. The second contribution brings an entirely new approach to vaccine uptake and responsiveness. Using an optical method, the authors show that the delivery of vaccine-containing nanoparticles to germinal centers can markedly alter the immune response and offer protective efficacy

against airborne influenza challenge. That spatial coordination plays such a vital role in vaccine efficacy raises the tantalizing possibility of leveraging such manipulation to improve existing vaccines [7, 8].

Innovations in Vaccine Engineering

Recent research has focused on virus-like particles (VLPs) and their application in the creation of vaccines for human and veterinary use. While studies have uncovered new aspects of VLP design and novel applications to therapeutic areas such as oncology, it is evident that new options for applying VLPs for vaccine development will need to be documented for initial implementation. New areas include the potential use of VLPs in combination with immune modulators in a separate prime-boost dose regimen or combination with other antigens, or for alternate routes of immunization such as intrauterine application. Current vaccine strategies have been focused on developing the next generation of vaccines intended to protect against bioterrorism agents. Because traditional methods for developing vaccines that use attenuated pathogens are not ethical, safe, or effective, new methods will need to focus on VLPs and their potential to generate highly efficacious vaccine products. Applications fall into three categories: 1) vaccines intended for use against cockroaches, 2) vaccines intended for use against pests with ongoing outbreaks, and 3) vaccines intended for high-biosecurity use against uncharacterized pests or agro-terrorism agents. Vaccines capable of generating neutralizing or opsonizing antibodies against intracellular pathogens are difficult to obtain. With the advent of recombinant DNA technology came the promise of vaccines capable of generating protective immunity against most pathogens. However, most current recombinant vaccines rely on the carrier approach. The carrier introduces an antigen-controlling vocalization at the front line of infection. The capacity of one or multiple defined antigens to induce immunity against enteropathogens or viral diseases by oral administration in the presence of adjuvants or by expression of plasmids or harmless bacterial/viral vectors is a substrate for future research. The fate and behavior of orally delivered particular antigens is a hot topic both for vaccinologists and dietitians [9, 10].

Challenges in Vaccine Development

Preventing infections with vaccines, a discovery once heralded as the "end of human infectious diseases," is not simple and straightforward. Insurance, health care, and new vaccines, however, are the most complex, costly, and lengthy human systems of product development that demand an inordinate number of hurdles to be overcome. Few scientific discoveries have led to worldwide changes, such as the hand-formed injectable vaccine by Massimo Del Guidance, the introduced killed vaccine by Emil von Behring, and the oral live attenuated vaccine by Albert Sabin. Each new treatment is a "pharmacon" that has potent effects both on the targeted cells and unintended targets, and thus, "safety" requirements vary from organisms to humans. With the coming of vaccines against COVID-19, widespread control of SARS-CoV-2 infection is anticipated, but vaccine hesitancy has become a controversial public concern. In the USA, the fatality rate of COVID-19 was 1.8 to 6.9 times higher in non-Hispanic black individuals than in white individuals, mainly related to social inequality, public health policies, health care access and utilization, and cultural beliefs. The creation of new vaccines is a slow, systematic, expensive, and laborious endeavor. It requires first identification of a promising target pathogen, followed by understanding of the biology and pathogenesis that permits rational vaccine development, innate and adaptive immune responses to the target pathogen that directs the best vaccine design, effective and safe vaccine platform and appropriate dose, adjuvants, and prime-booster schedule, assessment of immune responses, safety and protective efficacy in animal models, systematic phase 1 to phase 4 clinical trials exempt from serious adverse reactions, acceptability to scientists, physicians, public health officials, industry and vaccine developers, society, and effective worldwide vaccine distribution to achieve herd immunity [11, 12].

Ethical Considerations in Vaccinology

Advances in cynomolgus monkey and ferret immunogenicity models and human assays should lead to vaccines that protect against disease. All vaccines act by inducing antibodies that have effector functions, which neutralize a pathogen or create immune memory. However, these mechanisms differ in sophistication owing to the developmental stage of the species and the timing of vaccination or infection. For tissues that protect against disease, corresponding HIV viruses have not been isolated from infected humans; moreover, depending on the efficacy of the vaccine and the identification of the breakthrough infections, the patterns of humoral immune response differ. Advances in understanding the cellular response to HIV concern the development of averted subtype C neutralization, publicly known epitopes, and stratifying pre-antibody variants. The future of vaccinology will be grounded in engineering

potential vaccines that stably encode immunogenic antigens. Novel vaccine platforms that incorporate new vaccinology paradigms and strategies will need to deploy a range of sophisticated engineering approaches in order to incorporate naturally occurring epitopes into stably expressed recombinant vaccines that generate robust humoral and cellular responses. Integrating lineage and big data approaches will be needed to define rationally new vaccine approaches utilizing biochemistry and specialized systems biology to define T cell epitope-dependent approaches for rationally engineered vaccines that encode inducing mABs and T cell responses. Future vaccine development platforms will range over sophisticated engineering approaches, expanding beyond natural viruses, utilizing viruses from non-human primates and insects, as well as bacteria and yeast. Assistants trained with datasets of human health will need to advise clinicians in the rational development of vaccines. Where vaccine deployment is needed in low-resource nation's cooperation will be needed between these nations and the United Nations [13, 14].

Global Vaccine Initiatives

Coordination of vaccine R&D, clinical trials, and regulatory approval. Availability of funds for further development, acquisition of stocks, and vaccine delivery and administration. Effective partnerships have been developed at the global level. Remaining challenges in immunization coverage. Improvements are needed in data collection and dissemination systems. Greater emphasis on strengthening country capacity. Immunization of new cohorts of children with new vaccines against pneumococcal disease and rotavirus diarrhoea could prevent over 1 million deaths of children under the age of five each year. This number could exceed 3 million with the introduction of new vaccines against measles and rubella, and also against Japanese encephalitis and typhoid fever. Immunization coverage with current vaccines needs to be improved, as 24 million infants were not vaccinated against diphtheria, tetanus, and pertussis (DTP3) in the first year of life in 2007. The relative risk of death from measles and pneumococcal disease is several-fold greater in unimmunized than in immunized children. WHO has launched a new initiative to accelerate and expand measles control efforts. More vaccines against new pathogens or diseases are likely to be available for introduction in the next 10 years, particularly against dengue, tuberculosis, and malaria. New technologies are emerging, but due to the different natures of these vaccines, policies for their use should be carefully evaluated. The introduction of new vaccines poses challenges to the existing logistics and cold chain requirements. More attention needs to be paid to the purchasing and financing of the vaccines themselves, as they become more expensive and more complex. WHO and its immunization partners have identified a set of activities to accelerate the introduction of new life-saving vaccines. The country-maintained GAVI vaccine stock list needs to be expanded. Arbitrary deadlines for completion should be avoided. Greater understanding of vaccine delivery characteristics will lead to more efficient and acceptable methods for immunization service delivery [15, 16].

Future Trends in Vaccinology

The vaccine field has greatly benefited from technological advances, allowing the generation of vast amounts of data that enhance our understanding of biological processes. This approach, termed vaccinomics, merges Big Data, omics technologies, and bioinformatics for vaccine development and personalized vaccination. Vaccinology 3.0 utilizes advanced technologies to analyze each vaccine and identify alternative candidates based on known vaccines and the pathogen's characteristics. Candidates undergo rigorous in silico assessments before preclinical and clinical evaluations, where the best candidate is selected as a model vaccine. However, the current vaccine development pipeline primarily relies on conventional methodologies, limiting exploration of diverse antigens. Missed opportunities in technology-enabled investigations are significant, as vaccination has the potential to address all diseases affecting humanity. The threat of emerging diseases, such as those from the flavivirus or coronavirus families, poses risks for devastating pandemics, as seen with COVID-19's extensive impact. Investments in advanced technology platforms are essential for rapid vaccine discovery against potential bioterrorism threats, including anthrax and plague. Proposed solutions include early characterization of emerging pathogens for immediate and long-term vaccine development [17, 18].

Case Studies in Vaccine Development

To engender widespread use of vaccines against diseases currently lacking them, a systems biology approach is essential. A comprehensive genomic evaluation of pathogens has permitted the identification of surface-expressed potential vaccine candidates. Ideally, the selected target antigen evokes a strong TH1-type immune response, and its expression should suffer increased immunogenicity regarding the induction of the primary response. A multi-disciplinary network coupled with a rotating fund should lead

project development to fruition. A focus on pathogens and conditions where there are barriers to immunization and where proposed efforts have both immediate and long-term economic benefits is imperative. Adult diseases with high economic burdens as a result of lost productivity due to worker absences and associated costs to the health care system are candidates. In the short term, applying a systems biology approach that predicts effective targets of vaccine candidates could lead to new vaccines against a diverse range of diseases, including those currently neglected and affecting the developing world. Alternatively, vaccines for economic diseases such as HIV, tuberculosis, and malaria represent a panel of diseases against which it would be expected that the systems approach would lead to new vaccines. The importance of diseases that have barriers to vaccine development, where control strategies such as improved education are too slow and unrealistic, is emphasised. The aim would be to develop potentially successful candidate vaccine antigens and/or adjuvants and/or delivery vehicles for subsequent testing in animal models. Although initial predictions of diseases can be made based on genome sequence comparisons, the chosen antigen/subunit and delivery strategy/development pathway determine if the predictions are valid. Subsequently, there needs to be a higher-vantage discipline and an ongoing multi-disciplinary network to increase the probability of success. Where to set up the predictive tools and whether bigger, international collaborations are necessary are questions requiring a careful answer. The pathway from prediction to vaccine candidate requires the development of an intellectual property regime and economic partnerships [19, 20].

Public Health Implications of Vaccines

Vaccination has been one of the greatest global success stories and has transformed public health. However, vaccine coverage is not distributed equally, and there are constraints on the impact, sustainability, safety, and effects of vaccines. Immunisation saves more lives than any other initiated health intervention. There is increasing recognition of the need for proactive, concerted efforts to tackle vaccine-preventable diseases and to ensure access to vaccines for everyone, regardless of their circumstances. A more progressive view of vaccines takes into account their potential for providing broader benefits to human health and for addressing epigenetic causes of disease. This view brings new appreciation for the majesty of the immune system, celebrates the legacy of vaccination by thinking across societal to perpetual scales, and calls for enhanced stewardship of medicinal immune challenges by a commitment to concerted actions that champion equity, safety, discovery, and enhancement of vaccination for the benefit of all. Vaccines are effective, but there is an urgent need for more vaccines against infections that fall short, and there are still some vaccine-preventable diseases that continue to cause morbidity and mortality in many communities. Vaccines are sorely needed to address the health threats posed to hidden, poorly accessible, and marginal populations, and to tackle pathogens that could emerge and encroach within densely populated urban areas. There remains uneven access to vaccines and inequity in immunisation services, safety monitoring, and other essential components of vaccination campaigns. Vaccines are cumbersome and expensive to develop, and there are financial disincentives for more complex and riskier vaccines, including adjuvants and innovations that could improve efficacy. The commitment of the pharmaceutical industry is being buoyed by income prospects in emerging and developing economies. However, there remain weaknesses in surveillance systems, and low productivity and inefficiency in licensing procedures and regulatory oversight of vaccine development and safety. Collectively, these factors exaggerate the recent outbreaks of vaccine-preventable diseases. Some vaccine-preventable infections are transmitted by vectors that are outside the control of health authorities, and innovative technologies are being explored to develop vaccines that would be effective irrespective of developmental considerations, age, geography, or previous exposure. Vaccine-preventable diseases present unique opportunities for the extraction of mineral salts, which, if pursued smartly, could dramatically improve equity in health and HIV. Top-down approaches are required to ensure understanding of immunobiology and improve compatibility, distribution, presentation, and dosing form of vaccines that engender immunity against complex infections or in the presence of pathogenic interference [21, 22].

Future of Vaccine Research

About 47 human infectious agents have never stimulated the development of an effective vaccine, while barely successful vaccines could be improved by modern immunological theories and technologies. Vaccines derived from pathogens providing passive immunity, "old vaccines", are by far the most effective. Their shortcomings ushered in "new vaccines" designed by concepts in microbiology and immunology that introduced purity and stability. Live recombinant vaccines, "vaccine-mimetics" derived from the "de

novo" design of proteins evading tolerance, and therapeutic vaccines for cancers are *emerging changes*. It will take more than previously thought to cope with *hills and valleys*, "preclusion mechanisms," and with more modern hostile microbial nidia. Live heterogeneous "old vaccines" eliciting polyclonal antibodies to virulence antigens and cross-reacting with heterologous pathogens have provided humanity with passive immunity for millennia. This fortuitously acquired *heritage* underlies the intimate interdependency of ancient and modern mammals and chimeric neurons in the adaptive immunity of all vertebrates. Vaccines designed with polyclonal antibody responses derived from pathogens have reprogrammed susceptible and hybrid species inoculated before contact. Instinctively, the actionable epitope on virulence antigens has been misevaluated, assuming all hierarchical configurations behave equivalently. A large ensemble of *more than dual* bioreactivity, binding to the viral Rabies Antigen Protein, dependent on folding, post-translational hydrophobic and charge complementarity, leads to five human formulation designs of probing antibodies. The obvious possible approaches to improvement are cleverly tailored to elicit responses to virulence recycling antigens in vaccines in mammals, but more information from public immunology was steadfastly considered out of bounds. To take into account extreme species and chimeras with "impossible" neurotropic vaccines testing in geologic time, the target and the mnemonic responses' chair configurations were revised. Human vaccines have been designed applying biophysics and information computed here, solving shape domains/antigen-antibody interactions in tandem and bound energy in all species. The reshaping cellular division path of the density change identifies locations differentially binding to low and high-specific-energy antibodies [23, 24].

CONCLUSION

The future of vaccinology lies in the seamless integration of genomics, bioengineering, immunology, and big data to design vaccines that are more targeted, effective, and accessible. As the global burden of infectious and emerging diseases persists, there is an urgent need for innovative approaches such as reverse vaccinology, VLPs, and systems biology to address complex immunological challenges. The COVID-19 pandemic highlighted both the potential and the pitfalls of vaccine development, emphasizing speed, collaboration, and global equity. Overcoming barriers such as antigenic variability, intracellular pathogen resistance, and public skepticism will require not only scientific innovation but also ethical foresight and coordinated international policy. With advancements in personalized medicine and digital health, the next generation of vaccines may become safer, more adaptive, and universally deployable. A multidisciplinary approach involving scientists, governments, and global institutions is essential to ensure that the promise of modern vaccinology translates into practical and equitable solutions for all.

REFERENCES

1. Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?. PLoS pathogens. 2011 Dec 29;7(12):e1002344.
2. Barbosa T, Barral-Netto M. Challenges in the research and development of new human vaccines. Brazilian Journal of Medical and Biological Research. 2013 Feb;46(2):103-8.
3. Vishweshwaraiah YL, Dokholyan NV. Toward rational vaccine engineering. Advanced drug delivery reviews. 2022 Apr 1;183:114142.
4. Travieso T, Li J, Mahesh S, Mello JD, Blasi M. The use of viral vectors in vaccine development. npj Vaccines. 2022 Jul 4;7(1):75.
5. Gartlan C, Tipton T, Salguero FJ, Sattentau Q, Gorringe A, Carroll MW. Vaccine-associated enhanced disease and pathogenic human coronaviruses. Frontiers in immunology. 2022 Apr 4;13:882972.
6. Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoS Pathogens. 2022 Feb 17;18(2):e1010260.
7. Primorac D, Vrdoljak K, Brlek P, Pavelić E, Molnar V, Matišić V, Erceg Ivkošić I, Parčina M. Adaptive immune responses and immunity to SARS-CoV-2. Frontiers in immunology. 2022 May 4;13:848582. frontiersin.org
8. Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, Kisomi M, Shaikh N. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infectious Diseases and Therapy. 2023 Feb;12(2):367-87. springer.com
9. Henríquez R, Muñoz-Barroso I. Viral vector-and virus-like particle-based vaccines against infectious diseases: A minireview. Heliyon. 2024 Aug 15;10(15).

10. Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cellular & molecular immunology. 2022 Sep;19(9):993-1011.
11. Abdaal K, Batool A, Navid MT, Ahmed S, Qazi AS, Safdar W, Ali H, Rashid M, Rafaqat S. Advancements in vaccination strategies: from historical milestones to modern innovations in viral disease prevention and public health. Res J. Vet. Pract. 2024;12(1):11-21. researchgate.net
12. Jain A, Agarwal S, Sachdev R. Patenting Vaccines: A Two-Edged Sword. Indian JL & Legal Rsch.. 2021;2:1.
13. Nguyen TQ, Rollon R, Choi YK. Animal models for influenza research: strengths and weaknesses. Viruses. 2021 May 28;13(6):1011.
14. Blanset D, Di Piazza M, Musvasva E. Selection of Relevant Animal Models/Species. InTranslational Medicine 2021 Nov 25 (pp. 7-26). CRC Press.
15. Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Mellott CE, Marshall GS, Roberts CS. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics. 2022 Aug 1;150(3). aap.org
16. Dinleyici EC, Borrow R, Safadi MA, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Human vaccines & immunotherapeutics. 2021 Feb 1;17(2):400-7. tandfonline.com
17. Bragazzi NL, Gianfredi V, Villarini M, Rosselli R, Nasr A, Hussein A, Martini M, Behzadifar M. Vaccines meet big data: State-of-the-Art and prospects. From the classical 3Is ("Isolate–Inactivate–Inject") vaccinology 1.0 to vaccinology 3.0, vaccinomics, and beyond: a historical overview. Frontiers in public health. 2018 Mar 5;6:62.
18. Kennedy RB, Poland GA. The top five "game changers" in vaccinology: toward rational and directed vaccine development. Omics: a journal of integrative biology. 2011 Sep 1;15(9):533-7.
19. Lv Y, Zhang T, Cai J, Huang C, Zhan S, Liu J. Bioinformatics and systems biology approach to identify the pathogenetic link of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology. 2022 Sep 16;13:952987. frontiersin.org
20. Chen S, Qin R, Mahal LK. Sweet systems: technologies for glycomic analysis and their integration into systems biology. Critical reviews in biochemistry and molecular biology. 2021 May 4;56(3):301-20. tandfonline.com
21. Saleh A, Qamar S, Tekin A, Singh R, Kashyap R. Vaccine development throughout history. Cureus. 2021 Jul 26;13(7).
22. Dubé È, Ward JK, Verger P, MacDonald NE. Vaccine hesitancy, acceptance, and anti-vaccination: trends and prospects for public health. Annual review of public health. 2021 Apr 1;42(2021):175-91. annualreviews.org
23. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nature medicine. 2021 Apr;27(4):591-600.
24. Choy RK, Bourgeois AL, Ockenhouse CF, Walker RI, Sheets RL, Flores J. Controlled human infection models to accelerate vaccine development. Clinical Microbiology Reviews. 2022 Sep 21;35(3):e00008-21. nih.gov

CITE AS: Katu Amina H. (2025). The Future of Vaccinology: Engineering New Vaccines. Research Output Journal of Biological and Applied Science 5(3):119-125.
https://doi.org/10.59298/ROJBAS/2025/53119125